| Major bioactivities and mechanism of action of essential oils and their components NY Saad, CD Muller, A Lobstein Flavour and Fragrance Journal 28 (5), 269-279, 2013 | 302 | 2013 |
| AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD CR Giesige, LM Wallace, KN Heller, JO Eidahl, NY Saad, AM Fowler, ... JCI insight 3 (22), 2018 | 64 | 2018 |
| Pre-clinical safety and off-target studies to support translation of AAV-mediated RNAi therapy for FSHD LM Wallace, NY Saad, NK Pyne, AM Fowler, JO Eidahl, JS Domire, ... Molecular therapy Methods & clinical development 8, 121-130, 2018 | 56 | 2018 |
| Two-codon T-box riboswitch binding two tRNAs NY Saad, V Stamatopoulou, M Braye, D Drainas, C Stathopoulos, ... Proceedings of the National Academy of Sciences 110 (31), 12756-12761, 2013 | 37 | 2013 |
| A ribonucleopeptide world at the origin of life NY Saad Journal of systematics and evolution 56 (1), 1-13, 2018 | 30 | 2018 |
| Riboswitch (T-box)-mediated control of tRNA-dependent amidation in Clostridium acetobutylicum rationalizes gene and pathway redundancy for asparagine and asparaginyl-trnaasn … NY Saad, B Schiel, M Braye, JT Heap, NP Minton, P Duerre, HD Becker Journal of Biological Chemistry 287 (24), 20382-20394, 2012 | 25 | 2012 |
| Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy NY Saad, M Al-Kharsan, SE Garwick-Coppens, GA Chermahini, ... Nature communications 12 (1), 1-18, 2021 | 21 | 2021 |
| A glyS T-box riboswitch with species-specific structural features responding to both proteinogenic and nonproteinogenic tRNAGly isoacceptors M Apostolidi, NY Saad, D Drainas, S Pournaras, HD Becker, ... Rna 21 (10), 1790-1806, 2015 | 19 | 2015 |
| The DUX4 protein is a co‐repressor of the progesterone and glucocorticoid nuclear receptors J Quintero, NY Saad, SM Pagnoni, DK Jacquelin, LV Gatica, SQ Harper, ... FEBS letters 596 (20), 2644-2658, 2022 | 4 | 2022 |
| Engineering more efficient therapeutic miRNAs for FSHD gene therapy NY Saad, NK Pyne, J Copeland, SQ Harper MOLECULAR THERAPY 28 (4), 113-113, 2020 | 2 | 2020 |
| Investigation of the natural miRNA miR-675 as a prospective RNAi-based gene therapy product for facioscapulohumeral muscular dystrophy (FSHD) NY Saad, GA Chermahini, M Al-Kharsan, S Garwick-Coppens, SQ Harper MOLECULAR THERAPY 28 (4), 468-468, 2020 | 1 | 2020 |
| Compositions and methods for treating disease associated with dux4 overexpression N Saad, SQ Harper US Patent App. 18/274,327, 2024 | | 2024 |
| P65 Development of therapeutic extracellular vesicle enveloped-AAV vectors for muscle gene therapy J Kauffman, N Saad Neuromuscular Disorders 33, S75, 2023 | | 2023 |
| Post‐Translational Modifications of the DUX4 Protein Impact Toxic Function in FSHD Cell Models RN Knox, JO Eidahl, LM Wallace, SG Choudury, A Rashnonejad, ... Annals of neurology 94 (2), 398-413, 2023 | | 2023 |
| Acknowledgment to the Reviewers of Life in 2022 LE Office Life 13 (2), 2023 | | 2023 |
| P. 143 Investigation of human bone marrow mesenchymal stem cell-derived extracellular vesicles as therapeutic agents for Facioscapulohumeral muscular dystrophy L Wallace, S Harper, N Saad Neuromuscular Disorders 32, S106, 2022 | | 2022 |
| Translating DUX4-Targeted RNAi-Based Gene Therapy for FSHD LM Wallace, T Riley, N Saad, MJ Guggenbiller, GA Chermahini, ... MOLECULAR THERAPY 30 (4), 502-502, 2022 | | 2022 |
| Engineering More Efficient Therapeutic miRNAs for FSHD Gene Therapy NY Saad, LM Wallace, NK Pyne, J Copeland, M Guggenbiller, ... MOLECULAR THERAPY 30 (4), 279-279, 2022 | | 2022 |
| Acknowledgment to Reviewers of Life in 2021 Life Editorial Office Life 12 (2), 199, 2022 | | 2022 |
| Acknowledgment to Reviewers of Life in 2020 Life Editorial Office Life 11 (2), 73, 2021 | | 2021 |
Scott Q HarperThe Ohio State University and Nationwide Children's HospitalE-mailová adresa ověřena na: Nationwidechildrens.org
